Maarten van der Doelen

Patient-reported outcomes in mCRPC patients treated with radium-223 therapy

SUPPLEMENTARY MATERIAL

1 st

2 nd

3 rd

4 th

5 th

6 th

A

START

STOP

4 weeks

T0

T1

T2

1 st

2 nd

3 rd

4 th

B

START

STOP

4 weeks

4

T0

T1

T2

1 st

2 nd

C

START

STOP

4 weeks

T0

T1

Supplementary figure 1. Study schedule showing treatment schedule and time points (T0, T1, T2) of the provided questionnaires. A . The schedule for patients who completed radium-223 therapy. B-C . In case of early discontinuation of therapy, the patient was asked to complete an end-of-therapy questionnaire (time point T1 or T2) four weeks after the last received injection.

109